MedTrace Logo

Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC

NCT04691947 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2023-02-14

No results posted yet for this study

Summary

The objective is to determine the safety and immunogenicity of two different strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to demonstrate the safety and efficacy in prophylaxis of COVID-19.

Conditions

  • COVID-19 Vaccine

Interventions

BIOLOGICAL

ERUCOV-VAC

Vaccination on Day 0 and Day 21

OTHER

Placebo Vaccine

Placebo Vaccination on Day 0 and Day 21

Sponsors & Collaborators

  • TC Erciyes University

    collaborator OTHER

  • Health Institutes of Turkey

    lead OTHER_GOV

Principal Investigators

  • Zafer Sezer · Erciyes University Hakan Çetinsaya Iyi Klinik Uygulama ve Arastirma Merkezi, IKUM (Center for GCP)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-05
Primary Completion
2021-11-18
Completion
2021-11-18

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04691947 on ClinicalTrials.gov